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Abstract: Previously reported results suggest that the analogue of the somatostatin des-AA1,2,5[D-
Trp8,IAmp9]-somatostatin (CH-275) peptide bearing chelating agents able to coordinate radioac-
tive metals could be used for scintigraphic imaging of tumor lesions overexpressing sstr1. An
efﬁcient synthetic procedure for the preparation of the somatostatin analogue CH-275 and its
conjugate DTPAGlu–Gly–CH-275, bearing the chelating agent DTPAGlu (DTPAGlu  N,N-bis[2-
[bis(carboxy-ethyl)amino]ethyl]-L-glutamic acid) on the N-terminus, by solid-phase peptide synthe-
sis and 9-ﬂourenymethyoxycarbonyl (Fmoc) chemistry, is here reported. Rapid and efﬁcient labeling
of DTPAGlu–Gly–CH-275 was achieved by addition of 111In(III) to the compound. Typical yields
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were greater than 97% as determined by reversed phase high performance liquid chromatography
(HPLC) at speciﬁc activities in the range 4–9 GBq/mol (100–250 Ci/mmol). A preliminary
biological assay of the binding ability of 111In–DTPAGlu–Gly–CH-275 indicates, however, that the
labeled compound does not display any speciﬁc interaction with somatostatin sstr1 receptors in the
tested cell lines. To conﬁrm this unexpected negative result, competition binding experiments were
carried out, in which ﬁxed tracer amounts of the 125I-labeled somatostatin-14 were incubated with
the receptor-expressing cells in the presence of DTPAGlu–Gly–CH-275 or CH-275 at concentra-
tions ranging from 1010 to 103 M. While CH-275 shows a IC50 of 80 nM similar to that already
found in displacement experiments on CHO–K1 sstr1-transfected cells, DTPAGlu–Gly–CH-275
displays instead very low or negligible afﬁnity towards this receptor. The NMR solution charac-
terization indicates that the presence of DTPAGlu does not inﬂuence the conformational and
chemical features of the peptide moiety, thus suggesting that the loss in binding activity should be
due to steric hindrance of either the chelating agent DTPAGlu or its indium complex. © 2004
Wiley Periodicals, Inc. Biopolymers (Pept Sci) 76: 527–534, 2004
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INTRODUCTION
Somatostatin, a cyclic tetradecapeptide hormone se-
creted by the hypothalamus, plays important physio-
logical roles: it is a potent inhibitor of the release of
several hormones (i.e., growth hormone, insulin, glu-
cagons, gastrin) and it regulates many others biolog-
ical activities.1–3 It is also highly active in acrome-
galic patients, lowering the plasma level of growth
hormone, and therefore it is of potential therapeutic
value in clinical treatment of agromegaly and gastro-
enteropancreatic tumors.4
Somatostatin mediates its biological activities
through G-protein-coupled receptors, which possess
seven transmembrane-spanning helical domains. To
date, ﬁve human somatostatin receptor subtypes
(hsst1–5) have been cloned and characterized, but the
physiological role of each receptor subtype has not been
totally elucidated, although all of them are overex-
pressed by many cancer cells.5 The wide range of phys-
iological roles of somatostatin and its very short half-life
in plasma have led to substantial efforts to synthesize
analogues that exhibit potent and selective biological
activity with longer duration of action. The octapeptide
Octreotide6 is the most widely known somatostatin an-
alogue, being particularly efﬁcient in the treatment of
neuroendocrine tumors.7 Moreover, Octreotide deriva-
tives bearing a chelating agent on the N-terminal residue
and able to coordinate with high stability radioactive
metals [such as 111In(III)] have been developed for ap-
plications in cancer diagnosis and therapy by nuclear
medicine techniques.8 In fact, scintigraphy using soma-
tostatin analogues is a unique tool for diagnosis of neu-
roendocrine tumors, and radionuclide therapy offers
promising possibilities to limit tumor growth.9 Com-
pared to natural somatostatin, Octreotide contains a D-
tryptophan residue that enhances its potency and stabil-
ity. However, Octreotide does not show a high afﬁnity
for all ﬁve human sstr subtypes, since it prefers sstr2 and
sstr5, and to a lesser extent, sstr3, while it displays no
afﬁnity for sstr1 and sstr4.10 Therefore, Octreotide is
ineffective for the treatment of tumors expressing only
sstr1 or sstr4, and the radiometal-labeled Octreotide does
not help in the diagnosis and therapy by nuclear medi-
cine of sstr1- or sstr4-positive tumors.
Recently, a new family of 11-residue cyclic pep-
tides11 has been developed for selective binding of
sstr1. These peptides are characterized by the pres-
ence of the noncoded amino acid N-iso-propylamin-
omethylphenylalanine (IAmp) in the -turn region
that is considered responsible for receptor binding.12
The lead compound in this family is des-AA1,2,5[D-
Trp8,IAmp9]-somatostatin, known as CH-27513; it
displays very high afﬁnity and selectivity for sstr1.
From these observations, it appear reasonable to be-
lieve that CH-275 peptide derivatives, bearing chelat-
ing agents able to coordinate radioactive metals, could
be useful tools for scintigraphic imaging of tumor
lesions overexpressing sstr1.
In this article we describe the synthesis, the
111In(III) radiolabeling, and the biological behavior of
a CH-275 conjugate. This compound (Figure 1) con-
FIGURE 1 Schematic representation and amino acid
numbering scheme for DTPAGlu–Gly–CH-275. CH-275, a
somatostatin analogue, is des-AA1,2,5[D-Trp8,IAmp9]-so-
matostatin.
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tains the recently described DTPA derivative, the
chelating agent DTPAGlu14,15 bound to the N-termi-
nus of the peptide during solid-phase peptide synthe-
sis, and a glycine residue introduced as spacer be-
tween the chelating agent and the biologically active
CH-275 peptide. The NMR characterization of DT-
PAGlu–Gly–CH-275 is also reported to determine
structure–activity relationships on the binding mode
to the sstr1 receptor subtypes of this class of soma-
tostatin analogues.
EXPERIMENTAL
Materials and Methods
Benzotriazol-1-yl-oxy-tris-pyrrolidino-phosphonium (Py-
Bop), HOBt, all N-Fmoc-amino acid derivatives, and Rink
amide 4-methylbenzhydrylamine (MBHA) resin (HOBt:
1-hydroyxbenzotriazole; Fmoc: 9-ﬂourenylmethyoxycar-
bonyl) were purchased from Calbiochem-Novabiochem.
Boc–Amp–OH was obtained from ChemImpex. The DT-
PAGlu pentaester, the chelating agent fully protected by the
tert-butyl (tBu) groups on its carboxyl functions with the
exception of the carboxyl function on the side chain of
glutamic acid, N,N-bis[2-[bis[2-(1,1-dimethyletoxy)-2-
oxoethyl]-amino]ethyl]-L-glutamic acid 1-(1,1-dimethyleth-
yl)ester, was provided by Bracco Imaging SpA and used
without further puriﬁcation. Its synthesis is given in the
literature.14 Indium-111 was purchased from Nycomed Am-
ersham Sorin Srl in the chemical form of [111In]Cl3 (740
MBq/mL). 125I-Somatostatin-14 was obtained by Amer-
sham Biosciences. All other chemicals were commercially
available by Sigma-Aldrich and were used as received un-
less otherwise stated. Analytical reversed phase high per-
formance liquid chromatography (RP-HPLC) runs of Fmo-
c–IAmp(Z)–OH were carried out on a HPLC Shimadzu,
model 10A-LC, using a Phenomenex C18 column, 4.6  250
mm, eluted with a H2O/0.1% triﬂouroacetic acid (TFA) (A)
and CH3CN/0.1%TFA (B) linear gradient from 20 to 80%
over 40 min at a 1 mL/min ﬂow rate. Preparative RP-HPLC
runs were carried out on a Shimadzu apparatus using a
Phenomenex 22  250 mm, eluted with a H2O/0.1% TFA
(A) and CH3CN/0.1% TFA (B) linear gradient from 20 to
80% over 40 min at a 20 mL/ min ﬂow rate.
Solid-phase peptide synthesis was performed on a fully
automated peptide synthesizer Shimadzu SPPS-8. Analyti-
cal RP-HPLC runs of DTPAGlu–Gly–CH-275 and of CH-
275 peptides were carried out eluting with H2O/0.1% TFA
(A) and CH3CN/0.1% TFA (B) linear gradients from 5 to
70% over 30 min at a 1 mL/min ﬂow rate. Preparative
RP-HPLC runs were carried out eluting with H2O/0.1%
TFA (A) and CH3CN/0.1% TFA (B) linear gradients from
5 to 70% over 30 min at a 20 mL/ min ﬂow rate. Mass
spectra were recorded on a matrix-assisted laser desorption
ionization–time of ﬂight (MALDI–TOF) Vojager-DE (Per-
septive Biosystem). NMR experiments were carried out on
a Varian Unity 400-MHz spectrometer of the Centro Inter-
universitario di Ricerca sui Peptidi Bioattivi (CIRPeB) at
the University of Naples “Federico II.”
Protected Amino Acid Synthesis
Boc–IAmp–OH. The amount of 1.000 g Boc–Amp–OH
(3.4 mmol) was dissolved in 200 mL of acetone at room
temperature. The solution was acidiﬁed at pH 4 by adding
dropwise HCl 0.012 M. The atmosphere was purged with
N2 for 10 min, then 0.030 g (0.79 mmol) of NaBH4 and
0.020 g Pd/C 10% was added. The mixture was stirred
overnight, ﬁltered, and evaporated in vacuo. The amount of
0.900 g of the crude product was obtained as yellow oil
(2.67 mmol, 79% yield). The purity was tested by analytical
HPLC and 1H-NMR. HPLC-retention time (Rt) 12.9 min,
purity 98%; 1H-NMR(D2O).: 7.38 (2H, d, ArH), 7.31
(2H, d, ArH), 4.67 (1H, m, CH), 4.15 (2H, m, CH2NH),
3.45 [1H, m, CH(CH3)2], 3.13 (1H, dd CHHAr), 2.85 (1H,
dd CHHAr), 1.34 [6H, d CH(CH3)2], 1.32 [9H, s,C(CH3)3].
Boc–IAmp(Z)–OH. The amount of 0.900 g of Boc–
IAmp–OH (2.67 mmol) were dissolved in 120 mL of a
tetrahydrofuran (THF)/H2O 10/1 mixture. The pH was ad-
justed with 5.0 mL of NaOH 0.5 M. A solution of Z–OSu
(703 mg, 1 eq.) in 30 mL of THF was added dropwise at
0°C. After stirring for 2 h at room temperature, the product
was extracted with three portions of ethyl acetate. The
organic phase was dried under sodium sulfate, ﬁltered, and
evaporated in vacuo. The purity of the crude product (0.800
g, 1.69 mmol, yield 63%) was tested by analytical HPLC
and 1H-NMR. HPLC-Rt  26.0 min, purity  98%; 1H-
NMR(CDCl3). : 7.15 (4H, m, Phe–ArH), 7.36 (5H, br,
Cbz–ArH), 5.32 (2H, s, CH2–Cbz), 4.55 (1H, m, CH),
4.39 (2H, m, CH2NH), 4.25 [1H, m, CH(CH3)2], 3.1 (2H, m
CH2Ar) 1.10 [6H, d CH(CH3)2], 1.41 [9H, s,C(CH3)3].
H–IAmp(Z)–OH. A solution of Boc–IAmp(Z)–OH (1.69
mmol) dissolved in 50 mL of TFA/H20 80/20 was stirred for
6 h at room temperature. The solvent was removed in vacuo
and the pale yellow crude oil was obtained in good yield
(1.58 mmol, yield 93%). The analytical HPLC chromato-
gram of the crude product showed two peaks identiﬁed as
H–IAmp(Z)–OH and H–IAmp–OH by 1H-NMR spectros-
copy. Puriﬁcation of the crude mixture by preparative chro-
matography RP-HPLC afforded 0.250 g of H–IAmp(Z)–OH
(yield 40%). HPLC-Rt  19.1 min, purity  98%; 1H-
NMR(CD3OD).  7.20–7.40 (9H, br, ArH), 5.16 (2H, d,
CH2–Cbz), 4.45 (2H, s, CH2NH), 4.22 (1H, m, CH), 4.00
[1H, m, CH(CH3)2], 3.30 (1H, s, CHHAr), 3.05 (1H, m
CHHAr), 1.13 [6H, d CH(CH3)2].
Fmoc–IAmp(Z)–OH.
H–IAmp(Z)–OH (1.58 mmol) was dissolved in 40 mL of a
10% solution of Na2CO3. Thirty milliliters of dioxane were
added and the solution was cooled at 0°C. Then, Fmoc–OSu
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(1 eq.) dissolved in dioxane (10 mL) was added dropwise.
The mixture was stirred for 4 h at 0°C and overnight at room
temperature. The solution was concentrated and acidiﬁed to
pH 1 with 12 M HCl at 0°C, to achieve the ﬁnal compound
as a solid. The crude product was puriﬁed by RP-HPLC.
The amount of 0.573 g (yield 61%) was obtained and
characterized by analytical HPLC and 1H-NMR. HPLC-Rt
 28.0 min, purity  99%; 1H-NMR (CDCl3). : 7.75 (2H,
d, Fmoc), 7.53 (2H, br, Fmoc), 7.4–7.2 (4H, m, 2HFmoc,
2HAr), 7.30 (4H, m, 2HFmoc, 2HAr), 7.1 (5H, br, Cbz),
4.19–5.27 [8H, m, CH, CH2NH, CH2Fmoc, CH2–Cbz,
CH(CH3)2], 3.15 (1H, s, CHHAr), 3.10 (1H, m CHHAr),
1.09 [6H, d CH(CH3)2].
Peptide Synthesis
CH-275. Synthesis of des-AA1,2,5-[D-Trp8, IAmp9]-soma-
tostatin, CH-275, was carried out in the solid phase under
standard conditions using an Fmoc strategy. Cys(Trt)–
Wang preloaded resin (0.57 mmol/g, 0.057 mmol scale,
0.200 g) was used. Double couplings were performed with
addition of 4 equivalents of protected amino acids activated
by PyBop and HOBt and 6 equivalents of DIEA in DMF.
Stirring time was 60 min. When the sequence Fmoc–
Cys(trt)–Lys(Boc)–Phe–Phe–D-Trp(Boc)–IAmp(Z)–
Thr(tBu)–Phe–Thr(tBu)–Ser(tBu)–Cys(trt)–resin was
completed the Fmoc N-terminal protecting group was
removed by piperidine/dimethylformamide (DMF) 20/80
and the peptide–resin was divided in two portions.
The ﬁrst portion was cleaved with TFA containing tri-
isopropylsylane (2.0%), ethandithiole (2.5%), and water
(1.5%) over a period of 24 h, and the peptide products were
precipitated at 0°C by adding dropwise ethyl ether. In these
conditions, the Z-protecting group was partially lost. Puri-
ﬁcation of the crude mixture was carried out by RP-HPLC,
affording 60 mg of linear CH-275 (yield 70%). CH-275
(linear form) HPLC-Rt  25.6 min. MALDI–TOF MW
 1488. The disulﬁde bridge between Cys3 and Cys14 was
obtained at room temperature by 20 h spontaneous oxida-
tion in water solution containing 0.1 M NH4HCO3 (pH
 8.0) (1 mg of peptide per 1 mL of solution). The reaction
was monitored by Ellman’s test and the ﬁnal product ana-
lyzed by analytical HPLC and MALDI-TOF mass spectros-
copy. CH-275 (cyclic form) HPLC-Rt  25.1 min.
MALDI–TOF MW  1486.
DTPAGlu–Gly–CH-275.
The second portion of the resin containing CH-275 was
transferred in a vessel for the manual coupling of Fmoc–
Gly–OH and DTPAGlu pentaester. Fmoc–Gly–OH was
coupled to the N-terminal moiety of CH-275 in the same
way as the previous amino acid residues.
DTPAGlu pentaester was coupled to the Gly -amino
group using a 2.0 equivalent amount of DTPAGlu pen-
taester, 2.0 equivalents of O-(7-azabenzotriazol-1-yl)-
1,1,3,3-tetramethyluronium (HATU), and 4.0 equivalents of
N,N-diisopropylethylamine (DIPEA) in a single coupling.
The reaction was carried out by stirring the mixtures in
DMF for 3 h. For deprotection and cleavage, the fully
protected peptide resins were treated, over a period of 24 h,
with TFA containing tri-isopropylsylane (2.0%), ethandithi-
ole (2.5%), and water (1.5%). The peptide products were
precipitated at 0°C by adding ethyl ether dropwise. In these
conditions, the Z-protecting group was partially lost. Puri-
ﬁcation of the crude mixture was carried out by RP-HPLC
affording 50 mg of linear DTPAGlu–Gly–CH-275 (yield
44%). DTPAGlu–Gly–CH-275 (linear form) HPLC-Rt
 25.4 min. MALDI–TOF MW  1993. The disulﬁde
bridge between Cys3 and Cys14 was obtained at room tem-
perature by 20-h spontaneous oxidation in water solution
containing 0.1 M NH4HCO3 (pH  8.0) (1 mg of peptide
per 1 mL of solution). The reaction was monitored by
Ellman’s test and the ﬁnal product analyzed by analytical
HPLC and MALDI–TOF mass spectroscopy. DTPAGlu–
Gly–CH-275 (cyclic form) HPLC-Rt  24.9 min. MALDI–
TOF MW  1991.
Radiolabeling
The DTPAGlu–Gly–CH-275 peptide was dissolved in
CH3CN/ 20 % H2O at concentrations ranging between 0.1
and 1 mM. Prior to labeling, [111In]Cl3 was buffered by
adding 10 volumes of 0.3 M sodium citrate. One volume of
the peptide solution was then mixed with 10 volumes of
[111In]citrate and incubated for at least 1 h at room temper-
ature. Labeling efﬁciency was determined by Silica Gel-
TLC using 0.3 M Na-citrate as eluent, or RP-HPLC, which
was performed on a Gilson 305 system with an analytical
Vydac C18 column connected to a Beckman 170 radiode-
tector, using a H2O/0.1% TFA and CH3CN/0.1% TFA
gradient slightly different from the one described in the
previous paragraph (5– 70 % CH3CN/0.1% TFA over 31
min). The retention time was 22.0 min.
In Vitro Cellular Assays: Saturation
Binding Experiments
A plasmid containing the cDNA for the human sstr type 1
was kindly provided by Dr. Graeme Bell, University of
Chicago. A431 cells were stably transfected to overexpress
this receptor subtype. All in vitro cellular assays were
performed on cells that had been plated at a density of
1–200,000 cells/well in 12-well multiwell plates two or
three days prior to the experiments. These conditions al-
lowed for the cells to be almost conﬂuent at the time of the
assay. Experiments aimed at assessing speciﬁcity of inter-
action were performed by comparing cell-associated activ-
ity after incubation of the radiolabeled peptide with A431-
sstr1 and A431-control cells and with A431-sstr1 cells in
the presence of excess unlabeled peptide. Triplicate wells
were incubated with known amounts of radiolabeled peptide
for different times at 37°C. After incubation, cells were
washed with phosphate-buffered saline (PBS), pH 7.4, and
cells recovered by trypsinization. Cell-associated and total
radioactivity was determined with a Wallac Wizard gamma
530 Mansi et al.
counter. The amount of bound compound was normalized
for protein content that was determined by utilizing a com-
mercially available kit (Bio-Rad Laboratories) after solubi-
lizing cells in 1 N NaOH.
In Vitro Cellular Assays: Competition
Binding Experiments
Fixed tracer amounts of the 125I-labeled somatostatin-14
were incubated with the receptor-expressing cells in the
presence of DTPAGlu–Gly–CH-275 or CH-275 at concen-
trations ranging from 1010 to 103 M. The amount of
bound radioactivity was determined after 1 h at 4°C. Non-
linear regression analysis using a model for homologous
competition binding was performed using GraphPad Prism
(version 3.0a for Macintosh, GraphPad Software, San Diego
California USA, www.graphpad.com.) to derive the 50%
inhibitory concentration (IC50) for DTPAGlu–Gly–CH-275
and CH-275.
1H-NMR Spectroscopy
The solutions for NMR measurements were prepared by
dissolving 2.0 mg of DTPAGlu–Gly–CH-275 in 0.70 mL in
CD3CN/H2O in the ratio of 1:1. The spin system identiﬁ-
cation and assignment of individual resonances of DTPA-
Glu–Gly–CH-275 solutions were carried out by using a
combination of total correlated spectroscopy (TOCSY)16
and double quantum ﬁltered–correlated spectroscopy
(DQF–COSY) spectra.17 Sequence-speciﬁc assignment was
obtained by nuclear Overhauser effect spectroscopy
(NOESY)18 and rotating frame NOESY (ROESY) experi-
ments,19,20 according to the standard procedures.21
RESULTS AND DISCUSSION
Peptide Synthesis
The synthesis of CH-275 has been already reported by
Rivier and coworkers13 using solid-phase peptide syn-
thesis and t-butoxycarbonyl (Boc) chemistry. In order
to synthesize the CH-275 derivative containing the
chelating agent, we have changed the synthetic strat-
egy, setting up the best condition for solid-phase
peptide synthesis with Fmoc chemistry. For this pur-
pose, the non-natural amino acid derivative Fmoc–
IAmp(Z)–OH has been obtained according to scheme
reported in Figure 2 and it was fully characterized.
The secondary amine group on the IAmp side chain is
protected with the benzyl group (Z). This group is
partially lost when TFA treatment is performed to
remove the Boc-protecting group from the primary
-amine function. Therefore, the product mixture has
been separated by preparative HPLC in order to iso-
late the H–IAmp(Z)–OH-protected derivative. This
derivative is successively protected on the primary
-amino group with Fmoc, and then used in solid-
phase peptide synthesis. Solid-phase peptide synthesis
was performed on a fully automated peptide synthe-
sizer. When the peptide synthesis was complete, half
the amount of the resin containing the peptide was
treated for deprotection and cleavage to obtain CH-
275; the remaining part was used for peptide deriva-
tization with the glycine spacer and the DTPAGlu
chelating agent. The coupling step of the DTPAGlu
pentaester was very efﬁcient, while the subsequent
deprotection reaction required prolonged time to en-
sure complete removal of all the tert-butyl-protecting
groups. The prolonged treatment in TFA during the
deprotection and cleavage steps allows the almost
complete removal of the protecting group (Z) from the
secondary amine of the IAmp residue. At the end of
the synthesis, CH-275 and DTPAGlu–Gly–CH-275
were obtained as linear compounds in high yields, and
after puriﬁcation, spontaneous Cys–Cys oxidation in
basic buffer gave the desired cyclic compounds at
high purity.
The DTPAGlu chelating agent, chosen to derivat-
ize the CH-275 peptide, presents some advantages
among the chelating agents in use for radiometal
coordination in nuclear medicine applications. First,
the use of the chelating agent DTPAGlu allows us to
obtain a peptide conjugate having ﬁve carboxyl func-
tions and three amino groups available for radiometal
coordination. The total of eight chelating functions
constitute a coordinative set able to give stable metal
complexes, in particular with metal ions in the 3
oxidation state. There is one additional chelating
function compared to the coordinative set displayed
by DTPA directly bound to a peptide. The eight
functions displayed in the coordination set by our
peptide conjugate are in equal number to those uti-
lized by DTPA alone, which yields very stable com-
plexes. The additional coordinating moiety may pro-
vide better stability for chelating other radiometals of
interest, such as, for example, 90Y, which is used in
therapeutic applications and is known to form rather
unstable complexes with conventional DTPA-coupled
peptides. Second, the entire peptide conjugate is syn-
thesized in the solid phase, which allows us to obtain
high yields of the compound and high purity of the
raw product. The ﬁnal HPLC puriﬁcation step yields
a well-characterized compound that corresponds to
the desired molecule.
Radiolabeling and Biological Assays
Rapid and efﬁcient labeling of DTPAGlu–Gly–CH-
275 was obtained as early as 30 min after addition of
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111In(III) to the compound. Typical yields were
greater than 97% as determined by RP- HPLC at
speciﬁc activities ranging from 4 to 9 GBq/mol
(100–250 Ci/mmol). The good radiolabeling property
of the compound was consistent with the predicted
high efﬁciency of the DTPAGlu moiety to coordinate
In(III). A preliminary biological assay was performed
in order to verify the binding ability of 111In–DTPA-
Glu–Gly–CH-275 towards the sstr1 receptors ex-
pressed in cultured cells. Unexpectedly, the labeled
compound did not display any speciﬁc interaction
with sstr1 subtype receptors in the tested cell lines. In
fact, after cell incubation with the 111In-labeled com-
pound, cell-associated radioactivity was very low, and
the amount of bound compound, normalized for pro-
tein content, was negligible. To conﬁrm this surpris-
ing negative result, we have also performed competi-
tion binding experiments in which ﬁxed tracer
FIGURE 2 Synthetic schemes for the preparation of the amino acid derivative Fmoc–
IAmp(Z)–OH (a) and for the DTPAGlu–Gly–CH-275 peptide derivative (b).
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amounts of the 125I-labeled somatostatin-14 were in-
cubated with the receptor expressing cells in the pres-
ence of DTPAGlu–Gly–CH-275 or CH-275 at con-
centrations ranging from 1010 to 103 M. The
amount of bound radioactivity was determined after
1 h at 4°C and the results are reported in Figure 3.
Nonlinear regression analysis using a model for ho-
mologous competition binding allows us to derive the
50% inhibitory concentration (IC50) for DTPAGlu–
Gly–CH-275 and CH-275. While CH-275 shows a
IC50 of 80 nM, similar to that already observed in
displacement experiments on CHO–K1 sstr1-trans-
fected cells (IC50  30.9),11 DTPAGlu–Gly–CH-275
again displays very low or negligible afﬁnity towards
the sstr1 subtype receptor.
NMR Studies
Identiﬁcation of spin systems and assignment of individ-
ual resonances for DTPAGlu–Gly–CH-275 were ob-
tained by a combination of TOCSY16 and DQF-COSY
spectra.17 Sequence-speciﬁc assignment was obtained
by NOESY18 and ROESY experiments.19,20,21 Proton
chemical shifts for all the resonances at 298 K are listed
in Table I. The NOE pattern of DTPAGlu–Gly–CH-275
(data not shown) does not indicate the presence of a clear
preferred conformation of the peptide moiety, which is
presumably highly ﬂexible in the used experimental
conditions. Furthermore, the absence of NOE contacts
between DTPAGlu and CH-275 protons suggests that
DTPAGlu does not appreciably inﬂuence the conforma-
tion behavior of the cyclic peptide. In particular, the four
amino acids (residues 7 3 10) usually in a -turn
structure and involved in the interaction with the recep-
tor are not inﬂuenced by the presence of DTPAGlu and
should be able to adopt the right conformation receptor
binding.
Previous studies12 on the CH-275 peptide family
and its analogues have led to a model in which the
positively charged IAmp side chain interacts with
Asp137 in the receptor sstr1 subtype, while the iso-
FIGURE 3 Displacement of 125I somatostatin-14 with the
CH-275 peptide and the DTPAGlu–Gly–CH-275 peptide
conjugate, on A431 cells overexpressing the human sstr1
receptor subtype by stable transfection. IC50 values are
similar to published values for the CH-275 peptide, whereas
the DTPAGlu–Gly–CH-275 conjugate shows higher IC50
values (much lower afﬁnity). Similar results were obtained
in saturation experiments with 111In labelled DTPAGlu–
Gly–CH-275, where low afﬁnity for the sstr1 overexpress-
ing cells was observed (data not shown).
Table I 1H-NMR Parameters for the Peptide Derivative DTPAGlu–Gly–CH-275
Chemical Shifts (ppm) in CD3CN/ H20 1/1
Amino Acid NH  ()  ()  ()  () Others
Gly 8.69 4.36
Cys3 8.64 5.12 3.70–3.60
Lys4 8.58 4.82 1.62 2.01 CH 3.03; NH 7.89
Phe6 8.59 5.12 3.49–3.38
Phe7 8.56 4.98 3.38–3.38
D-Trp8 8.34 4.75 3.35–3.35 NH 10.34; H2 7.38; H4 7.87; H5–H7 7.56–7.20
IAmp9 8.36 5.11 3.41–3.34 Har 7.71–7.51; CH2 3.30; CH 3.72; CH3 1.71
Thr10 8.17 4.78 4.75 1.53 OH 5.04
Phe11 8.61 5.11 3.48–3.29 Har 7.52–7.40
Thr12 8.45 4.88 4.56 1.56
Ser13 8.44 4.93 4.32–4.32
Cys14 8.61 5.11 3.48–3.29
DTPAGlu 3.96 2.34 3.85 CH2CO 2.95; CH2CH2N 2.55–2.94
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propyl group experiences hydrophobic interaction
with the side chain of Leu107. The proposed interac-
tions thus indicate that this class of peptide ligand
interacts with the sstr1 receptor subtype in a binding
pocket within the transmembrane 2 and 3 domains.
On the basis of these observations, DTPAGlu–Gly–
CH-275 derivatives bearing a chelating agent would
be expected to get deeper in the pocket of receptor
sstr1 subtype, as the biologically active CH-275 pep-
tide does, since the same conformational and chemi-
cal features should have been maintained. This as-
sumption, however, has not been conﬁrmed by the
experimental data, presumably because the presence
of DTPAGlu does not allow the DTPAGlu–Gly–CH-
275 derivative to entry into the binding pocket of sstr1
receptor subtype, due to the increased steric hindrance
of the chelating moiety.
CONCLUSIONS
The peptide family of CH-275 and its analogues rep-
resent a very important class of somatostatin ana-
logues for their ability in selective binding of
sstr1receptor subtype. Unfortunately, as indicated by
saturation and competition binding experiments on
cells expressing sstr1, the CH-275 derivative bearing
the DTPAGlu chelating agent on the N-terminal end
loses its binding property towards the sstr1 receptor.
The NMR results indicate that the presence of DT-
PAGlu does not inﬂuence the conformational and
chemical features of peptide moiety, and particularly
that of the four amino acids (residues 73 10) usually
responsible for binding; therefore the loss of binding
activity should be attributed to the steric hindrance or
to the charges of both DTPAGlu (5 additional nega-
tive charges) and the complex 111In–DTPAGlu (2
additional negative charges). In fact, it is known7 that
the binding sites for somatostatin in its receptors are
deeply embedded in the membrane and therefore the
surface charge on the membrane could repel our
charged conjugates. The introduction of a long space
between the bioactive peptide CH-275 and the indium
complex of DTPAGlu should enable us to recover the
speciﬁc binding ability toward the sstr1 receptor sub-
type.
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